Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Michael Koren, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
Michael Miller, MD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.